John R Holancin, MD | |
132 Hospital Dr, Mc Kenzie, TN 38201-1637 | |
(731) 352-7435 | |
(731) 352-0573 |
Full Name | John R Holancin |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 132 Hospital Dr, Mc Kenzie, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1528035797 | NPI | - | NPPES |
3165810 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | MD11195 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
John R Holancin, MD Po Box 400, Jackson, TN 38302-0400 Ph: (731) 423-8697 | John R Holancin, MD 132 Hospital Dr, Mc Kenzie, TN 38201-1637 Ph: (731) 352-7435 |
News Archive
The Centers for Disease Control and Prevention may have increased the threat of COVID-19 infection in the Black community and among some other racial and ethnic minority groups when the agency updated its mask guidance last May, according to a new commentary in the Journal of General Internal Medicine by two colleagues at Massachusetts General Hospital.
There may be a way for older people to prevent natural aging of their minds, and it could be as simple as playing a video game.
SIGA Technologies, Inc., a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today the successful completion of its fourth human clinical trial, supporting the safety and tolerability of the anticipated clinical dose of ST-246®, SIGA's lead smallpox antiviral drug candidate.
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.
Generex Biotechnology Corporation announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18, 2011 in Cambridge, MA.
› Verified 2 days ago
Dr. Joseph Charles Opie, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 205 Hospital Dr, Suite A, Mc Kenzie, TN 38201 Phone: 731-352-7907 Fax: 731-352-4459 |